Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 14 of 46

Clinically Significant Outcomes of Interest (1 of 2)

Outcomes that were reported in the reviewed studies and analyzed in the CER include intermediate outcomes, such as disease activity and symptoms with assessment by physician global assessment of disease activity; by symptom response, for example, measured as the American College of Rheumatology Pediatric Improvement Score (e.g., 20%, 30%, or 50% from baseline); by parent/patient global assessments of well-being; and by active joint count. Laboratory measures of inflammation, such as erythrocyte sedimentation rate (ESR), and radiographic evidence of progression were other outcomes of interest.